Literature DB >> 26775929

Device-associated infection rates, bacterial resistance, length of stay, and mortality in Kuwait: International Nosocomial Infection Consortium findings.

Haifaa Hassan Al-Mousa1, Abeer Aly Omar1, Víctor Daniel Rosenthal2, Mona Foda Salama3, Nasser Yehia Aly4, Mohammad El-Dossoky Noweir5, Flavie Maria Rebello3, Dennis Malungcot Narciso3, Amani Fouad Sayed5, Anu Kurian5, Sneha Mary George5, Amna Mostafa Mohamed5, Ruby Jose Ramapurath5, Suga Thomas Varghese5.   

Abstract

BACKGROUND: To report the results of the International Infection Control Consortium (INICC) study conducted in Kuwait from November 2013-March 2015.
METHODS: A device-associated health care-acquired infection (DA-HAI) prospective surveillance study in 7 adult, pediatric, and neonatal intensive care units (ICUs) using the U.S. Centers for Disease Control and Prevention's (CDC's) National Healthcare Safety Network (NHSN) definitions and INICC methods.
RESULTS: We followed 3,732 adult and pediatric patients for 21,611 bed days and 671 neonatal patients for 4,515 bed days. In the medical-surgical ICUs, the central line-associated bloodstream infection (CLABSI) rate was 3.5 per 1,000 central line days, the ventilator-associated pneumonia (VAP) rate was 4.0 per 1,000 mechanical ventilator days, and the catheter-associated urinary tract infection (CAUTI) rate was 3.3 per 1,000 urinary catheter days; all of them were lower than INICC rates (CLABSI: 4.9; VAP: 16.5; and CAUTI: 5.3) and higher than NHSN rates (CLABSI: 0.9; VAP: 1.1; and CAUTI: 1.2). Resistance of Staphylococcus aureus to oxacillin was 100%, resistance of Acinetobacter baumannii to imipenem and meropenem was 77.6%, and resistance of Klebsiella pneumoniae to imipenem and meropenem was 29.4%. Extra length of stay was 27.1 days for CLABSI, 22.2 days for VAP, and 19.2 days for CAUTI in adult and pediatric ICUs. Extra crude mortality was 19.9% for CLABSI, 30.9% for VAP, and 11.1% for CAUTI in adult and pediatric ICUs.
CONCLUSIONS: DA-HAI rates in our ICUs are higher than the CDC-NSHN rates and lower than the INICC international rates.
Copyright © 2016 Association for Professionals in Infection Control and Epidemiology, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Hospital infection; antibiotic resistance; bloodstream infection; catheter-associated urinary tract infection; central line–associated bloodstream infections; health care–associated infection; network; nosocomial infection; urinary tract infection; ventilator-associated pneumonia

Mesh:

Year:  2016        PMID: 26775929     DOI: 10.1016/j.ajic.2015.10.031

Source DB:  PubMed          Journal:  Am J Infect Control        ISSN: 0196-6553            Impact factor:   2.918


  13 in total

1.  Device-Associated Healthcare-Associated Infections (DA-HAI) and the caveat of multiresistance in a multidisciplinary intensive care unit.

Authors:  Inam Danish Khan; Atoshi Basu; Sheshadri Kiran; Shaleen Trivedi; Priyanka Pandit; Anupam Chattoraj
Journal:  Med J Armed Forces India       Date:  2016-12-16

2.  Rhamnolipid Nano-Micelles versus Alcohol-Based Hand Sanitizer: A Comparative Study for Antibacterial Activity against Hospital-Acquired Infections and Toxicity Concerns.

Authors:  Yasmin Abo-Zeid; Marwa Reda Bakkar; Gehad E Elkhouly; Nermeen R Raya; Dalia Zaafar
Journal:  Antibiotics (Basel)       Date:  2022-04-29

3.  Morbidity, mortality, and emerging drug resistance in Device-associated infections (DAIs) in intensive care patients at a 1000-bedded tertiary care teaching hospital.

Authors:  Inam Danish Khan; Geetanjali Gonimadatala; S Narayanan; Umesh Kapoor; Harleen Kaur; Anuradha Makkar; R M Gupta
Journal:  Med J Armed Forces India       Date:  2021-10-28

4.  Impact of the International Nosocomial Infection Control Consortium (INICC) multidimensional approach on rates of ventilator-associated pneumonia in intensive care units of two hospitals in Kuwait.

Authors:  Haifaa Hassan Al-Mousa; Abeer Aly Omar; Víctor Daniel Rosenthal; Mona Foda Salama; Nasser Yehia Aly; Mohammad El-Dossoky Noweir; Flavie Maria Rebello; Dennis Malungcot Narciso; Amani Fouad Sayed; Anu Kurian; Sneha Mary George; Amna Mostafa Mohamed; Ruby Jose Ramapurath; Suga Thomas Varghese; Pablo Wenceslao Orellano
Journal:  J Infect Prev       Date:  2018-03-23

5.  Risk factors for hospital-acquired infections in teaching hospitals of Amhara regional state, Ethiopia: A matched-case control study.

Authors:  Walelegn Worku Yallew; Abera Kumie; Feleke Moges Yehuala
Journal:  PLoS One       Date:  2017-07-18       Impact factor: 3.240

6.  Multi-Drug Resistant Organisms Infection Impact on Patients Length of Stay in Respiratory Care Ward.

Authors:  Yi-Ping Chen; Xian-Wen Tasi; Ko Chang; Xuan-Di Cao; Jung-Ren Chen; Chien-Sen Liao
Journal:  Antibiotics (Basel)       Date:  2021-05-20

7.  Knowledge, awareness, and attitude regarding infection prevention and control among medical students: a call for educational intervention.

Authors:  Awab Ali Ibrahim; Sittana Shamseldin Elshafie
Journal:  Adv Med Educ Pract       Date:  2016-08-22

8.  Incidence, clinical features, and implications on outcomes of neonatal late-onset sepsis with concurrent infectious focus.

Authors:  I-Hsyuan Wu; Ming-Horng Tsai; Mei-Yin Lai; Lee-Fen Hsu; Ming-Chou Chiang; Reyin Lien; Ren-Huei Fu; Hsuan-Rong Huang; Shih-Ming Chu; Jen-Fu Hsu
Journal:  BMC Infect Dis       Date:  2017-07-03       Impact factor: 3.090

9.  An observational case study of hospital associated infections in a critical care unit in Astana, Kazakhstan.

Authors:  Dmitriy Viderman; Yekaterina Khamzina; Zhannur Kaligozhin; Makhira Khudaibergenova; Agzam Zhumadilov; Byron Crape; Azliyati Azizan
Journal:  Antimicrob Resist Infect Control       Date:  2018-04-25       Impact factor: 4.887

10.  Prevention of Surgical Site Infections: A Systematic Review of Cost Analyses in the Use of Prophylactic Antibiotics.

Authors:  Abdul K R Purba; Didik Setiawan; Erik Bathoorn; Maarten J Postma; Jan-Willem H Dik; Alex W Friedrich
Journal:  Front Pharmacol       Date:  2018-07-18       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.